ProCertus BioPharm of Madison has completed an additional $1.7 million round of financing. 

The company is developing therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy.

Current investors Novartis Venture Fund and Venture Investors led the financing and were joined by the Wisconsin Alumni Research Foundation.

Read full Wisconsin State Journal story here.